L-LOP/LOPP for the treatment of canine gastrointestinal/ hepatosplenic lymphoma

Canine gastrointestinal (GI) and hepatosplenic (HS) high-grade (large cell) lymphomas are uncommon forms of canine lymphomas, with a very poor response to chemotherapy and a very poor prognosis. Currently, there are no established effective chemotherapy protocols for canine GI/HS lymphomas. This case series aimed to retrospectively evaluate the efficacy of lomustine-based protocols L-LOP (L-asparaginase, lomustine, vincristine, and prednisolone) and L-LOPP (with the addition of procarbazine) for treatment of canine GI/HS lymphomas. Medical records of dogs with cytologically or histologically diagnosed lymphoma at CityU Veterinary Medical Centre from 2019 to 2022 were retrospectively reviewed. The L-LOP/LOPP treatment protocol was well tolerated with rare severe adverse events. Median progression-free survival for GI and HS lymphoma was 56  days (range, 10–274  days) and 57  days (range 8–135  days) respectively; while median survival time for GI and HS lymphoma was 93  days (range 10–325  days) and 210  days (range 8–240  days) respectively. © 2024 Lai, Horta, Almendros, Ha and Giuliano. © 2024 Lai, Horta, Almendros, Ha and
Giuliano